A compound comprising a modified oligonucleotide, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide consists of 16-19 contiguous nucleosides of the following nucleoside pattern V in the 5’ to 3’ orientation: NM NB (NQ NQ NB NB)4 NZ wherein NM is a modified nucleoside that is not a bicyclic nucleoside； each NB is a bicyclic nucleoside； each NQ is a non-bicyclic nucleoside； and Nz is a modified nucleoside. Also disclosed is the use of said compound in the treatment of fibrosis and associated diseases.
